Myths vs facts: CYP2D6 and Wechseljahre

CYP2D6 is a liver enzyme that metabolizes many drugs, including those used during menopause (e.g., tamoxifen, certain antidepressants). A common myth is that your CYP2D6 genotype directly determines whether you will have severe menopausal symptoms or when menopause starts. This is not supported by evidence. The fact is: CYP2D6 variants affect how efficiently your body processes specific medications. For tamoxifen (used in breast cancer risk reduction), being a 'poor metabolizer' can reduce efficacy. For antidepressants prescribed for hot flashes, dose adjustments may be needed. However, there is no strong evidence that CYP2D6 directly controls hormone levels or the timing of menopause. Menopause is a complex endocrine process influenced by many genes and lifestyle factors. A standalone CYP2D6 DNA test is not a diagnostic tool for menopause. MyBody-X tests are lifestyle products, not clinical diagnostics. If you are taking medications during menopause, discuss your genetics with a doctor – especially for tamoxifen or opioid painkillers (codeine, tramadol) that are also metabolized by CYP2D6. Avoid self-medicating or changing doses based solely on genotype.